



immuron

**ORAL IMMUNOTHERAPY
USING BOVINE ANTIBODIES**

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

2013: THE ACHIEVEMENTS



New Shareholders	<ul style="list-style-type: none">✓ April rights issue: high networth investors who provide a lot of support
Travelan: continue commercialization	<ul style="list-style-type: none">✓ Direct-to-wholesale model in Australia, increase revenues✓ Regulatory approval in Canada✓ Regulatory progress in licensed territories✓ Discussions in the US progressing
Fatty Liver / NASH	<ul style="list-style-type: none">✓ Continue preparation for Phase IIb Clinical trial✓ ASH trial cleared by FDA✓ Industry (potential partner) interest
Clostridium Difficile and other RD	<ul style="list-style-type: none">✓ Very encouraging preventative result. Treatment studies ongoing.✓ A number of promising applications, including for orphan conditions

LOOKING AHEAD

What we are seeking to achieve




Financial Strength	<ul style="list-style-type: none">➤ Improve balance sheet
Travelan: continue commercialization	<ul style="list-style-type: none">➤ US Travelan transaction➤ More licenses and more revenue
Fatty Liver / NASH	<ul style="list-style-type: none">➤ Commence Phase IIb Clinical trial➤ Partner
Progress RD	<ul style="list-style-type: none">➤ Progress to the clinic with another product➤ A number of promising applications, including for orphan conditions

We continue to nurture and benefit from strong partnerships with our research and development collaborators and with our commercial partners.

TRAVELAN

The last 3 years




TRAVELAN
Before July 2013


Immuron

Immuron

Takeda




Wholesalers




**R
e
t
a
i
l
e
r
s**



Immuron is commanding substantially higher margin





IMM-124E for NASH


Mechanism of Action

Immuron

Oral Immunotherapy: An approach to treating autoimmune, infectious and inflammatory disease through the oral delivery of antibodies

There is continually growing scientific support for Immuron's approach

Immuron has the right product at the right time



IMM-124E for NASH

Ready to go: Phase 2B trial

Immuron



Based on existing technology:

- Mature manufacturing process
- High Safety profile



IND cleared by the FDA: Immuron set to commence clinical trials

Preparations under way

Investigators identified



IMM-124E has been independently validated:

selected as only 1 of 3 products to be studied for alcoholic steatohepatitis (ASH) under a fully funded NIH TREAT study


NASH remains a very large unmet medical need of significant interest to the medical profession and the pharmaceutical industry

Clostridium difficile (C.diff): a bacteria normally found in people's intestines

- Certain circumstances C.diff can multiply and its toxin causes illness such as diarrhoea & severe inflammation of the bowel

C. diff infection accounts for:

- considerable increases in length of hospital stays
- more than US\$3.2 billion in health care costs each year in the United States









IMM-529 for Clostridium Difficile

Very encouraging results to date

Immuron

- IMM-529 under collaboration with Monash University
- All data owned by Immuron
- IMM-529 demonstrated positive pre-clinical results:
 - Encouraging preventative data
 - Treatment effect currently being investigated
 - Proprietary vaccine given to cows being improved



Thank you

Contact

Amos Meltzer – Chief Executive Officer

0437 587 680